| Authors: |
Shen JX; Bristol Myers Squibb, Lawrenceville, New Jersey, USA. jim.shen@bms.com., Dodge R; Princeton, New Jersey, USA. rob.dodge22@outlook.com., Oberstein S; Takeda Pharmaceutical Company Limited, Tokyo, Japan., Cunliffe J; Novartis, Cambridge, Massachusetts, USA., Ramani V; Celerion, Lincoln, Nebraska, USA., Mohana Sundaram S; Celerion, Lincoln, Nebraska, USA., Santos IC; Bristol Myers Squibb, Lawrenceville, New Jersey, USA., Yu C; US Food and Drug Administration, Silver Spring, Maryland, USA., Dholakiya SL; Bristol Myers Squibb, Lawrenceville, New Jersey, USA., Kumar S; Pioneering Medicines at Flagship Pioneering Inc., Cambridge, Massachusetts, USA., Xu XS; Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Fraser S; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Mokhtari Z; Takeda Pharmaceutical Company Limited, Tokyo, Japan., Yin F; Takeda Pharmaceutical Company Limited, Tokyo, Japan., Rizzo DG; AbbVie Inc., North Chicago, Illinois, USA., Barnaby OS; Thousand Oaks, Amgen, California, USA., Shen H; Merck & Co., Inc., Rahway, New Jersey, USA., Warrino DE; KCAS Bio, Olathe, Kansas, USA., Awasthi S; Merck & Co., Inc., Rahway, New Jersey, USA., Burke K; Johnson & Johnson, New Brunswick, New Jersey, USA., Schaffer S; Johnson & Johnson, New Brunswick, New Jersey, USA., Rathi A; BioAgilytix Boston, Boston, Massachusetts, USA. |
